An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 28 Feb 2018 Planned End Date changed from 27 Jun 2018 to 25 Mar 2020.
- 31 Jan 2018 Planned end date changed from 25 Mar 2020 to 27 Jun 2018.
- 31 Jan 2018 Planned primary completion date changed from 5 Jul 2019 to 2 May 2018.